Oral Anticancer Medication
Oral anticancer medications (OAMs) have been used for decades to treat and reduce the risk of a variety of cancers. With the exponential increase in the number of oral medications developed, including cytotoxic agents, hormonal agents, small-molecule inhibitors, and agents targeted at receptors that regulate cellular differentiation and growth, cancer programs are developing workflows, education, and symptom management programs to ensure that patients follow their prescribed treatments. As a result, clinicians need evidence-based guidelines to assist patients in achieving the best possible outcomes as nonadherence to OAMs can lead to suboptimal responses to therapy.
ONS account holders enjoy access to more clinical, evidence-based practice information.